Gretchen focuses her practice on corporate transactions, securities, mergers and acquisitions, and general corporate matters. She works with public and private companies of all sizes, including emerging companies.
While earning her JD, Gretchen interned with a Massachusetts law firm, where she assisted with real estate refinancings and purchases. She also served as a judicial extern for the Honorable Ronald S. W. Lew of the United States District Court for the Central District of California. In that role, she drafted bench memoranda involving claims of tortious interference with economic advantage, RICO, breach of contract, trademark infringement, and unfair competition. In addition, Gretchen was a teaching assistant for a Mediation Advocacy course and a law clerk for Neighborhood Legal Services of Los Angeles.
In law school, Gretchen earned a Business Law Certificate, and was a quarterfinalist and an editor of the Hale Moot Court Honors Program.
News & Press
Mintz advised the underwriters in connection with a $90 million underwritten offering by Rezolute, Inc. of 20,786,923 shares of common stock and pre-funded warrants to purchase up to 6,905,385 shares of common stock. The common stock is listed on the Nasdaq Capital Market under the symbol “RZLT.”
Mintz represented the US Department of Energy (DoE) Loan Programs Office (LPO) in the closing of a $1.45 billion loan guarantee to Hanwha Q Cells Georgia, Inc. (QCells), a leading North American crystalline silicon solar manufacturer.
Mintz Secures Motion to Dismiss Victory for DermTech Execs in Test Patch Revenue Suit
December 06, 2024
Mintz announced that it successfully obtained the dismissal of all claims alleged in a shareholder class action against the former senior executives of DermTech, Inc., a San Diego-based life sciences company focused on medical technology and testing in the dermatological field.
Mintz Advises ArriVent BioPharma on $175M Nasdaq IPO
February 01, 2024
Mintz Members John Rudy and Matthew T. Simpson led the team that advised ArriVent Biopharma, Inc. on its initial public offering (IPO) on the Nasdaq Global Market. This was the second biotech IPO of 2024. ArriVent is a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics.
SAN FRANCISCO – Mintz represented Ray Therapeutics, a San Francisco, CA-based optogenetics company, in the completion of an upsized and oversubscribed $100 million Series A financing round.
Recent Insights
Mintz advised the underwriters in connection with a $90 million underwritten offering by Rezolute, Inc. of 20,786,923 shares of common stock and pre-funded warrants to purchase up to 6,905,385 shares of common stock. The common stock is listed on the Nasdaq Capital Market under the symbol “RZLT.”
Mintz represented the US Department of Energy (DoE) Loan Programs Office (LPO) in the closing of a $1.45 billion loan guarantee to Hanwha Q Cells Georgia, Inc. (QCells), a leading North American crystalline silicon solar manufacturer.
Mintz announced that it successfully obtained the dismissal of all claims alleged in a shareholder class action against the former senior executives of DermTech, Inc., a San Diego-based life sciences company focused on medical technology and testing in the dermatological field.
